Login / Signup

Increased risk of infection reporting with anti-BCMA bispecific monoclonal antibodies in multiple myeloma: A worldwide pharmacovigilance study.

Adrien ContejeanCécile JanssenFrédérique Orsini-PiocelleCéline ZecchiniCaroline CharlierLaurent Chouchana
Published in: American journal of hematology (2023)
Keyphrases
  • multiple myeloma
  • adverse drug
  • emergency department